These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 32017179)
1. An overview of international regulatory frameworks for mesenchymal stromal cell-based medicinal products: From laboratory to patient. López-Beas J; Guadix JA; Clares B; Soriano-Ruiz JL; Zugaza JL; Gálvez-Martín P Med Res Rev; 2020 Jul; 40(4):1315-1334. PubMed ID: 32017179 [TBL] [Abstract][Full Text] [Related]
2. A Worldwide Overview of Regulatory Frameworks for Tissue-Based Products. Oberweis CV; Marchal JA; López-Ruiz E; Gálvez-Martín P Tissue Eng Part B Rev; 2020 Apr; 26(2):181-196. PubMed ID: 31910099 [TBL] [Abstract][Full Text] [Related]
3. Principal Criteria for Evaluating the Quality, Safety and Efficacy of hMSC-Based Products in Clinical Practice: Current Approaches and Challenges. Guadix JA; López-Beas J; Clares B; Soriano-Ruiz JL; Zugaza JL; Gálvez-Martín P Pharmaceutics; 2019 Oct; 11(11):. PubMed ID: 31652984 [TBL] [Abstract][Full Text] [Related]
4. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective. Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215 [TBL] [Abstract][Full Text] [Related]
5. Mesenchymal Stromal Cells Anno 2019: Dawn of the Therapeutic Era? Concise Review. Hoogduijn MJ; Lombardo E Stem Cells Transl Med; 2019 Nov; 8(11):1126-1134. PubMed ID: 31282113 [TBL] [Abstract][Full Text] [Related]
7. Access to medicines for rare diseases: A European regulatory roadmap for academia. Rosenberg N; van den Berg S; Stolwijk NN; Jacobs BAW; Post HC; Pasmooij AMG; de Visser SJ; Hollak CEM Front Pharmacol; 2023; 14():1142351. PubMed ID: 36925633 [No Abstract] [Full Text] [Related]
8. Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development. Ancans J Front Immunol; 2012; 3():253. PubMed ID: 22912639 [TBL] [Abstract][Full Text] [Related]
9. Speeding Access to Vaccines and Medicines in Low- and Middle-Income Countries: A Case for Change and a Framework for Optimized Product Market Authorization. Ahonkhai V; Martins SF; Portet A; Lumpkin M; Hartman D PLoS One; 2016; 11(11):e0166515. PubMed ID: 27851831 [TBL] [Abstract][Full Text] [Related]
10. Rationale and design of the allogeneiC human mesenchymal stem cells (hMSC) in patients with aging fRAilTy via intravenoUS delivery (CRATUS) study: A phase I/II, randomized, blinded and placebo controlled trial to evaluate the safety and potential efficacy of allogeneic human mesenchymal stem cell infusion in patients with aging frailty. Golpanian S; DiFede DL; Pujol MV; Lowery MH; Levis-Dusseau S; Goldstein BJ; Schulman IH; Longsomboon B; Wolf A; Khan A; Heldman AW; Goldschmidt-Clermont PJ; Hare JM Oncotarget; 2016 Mar; 7(11):11899-912. PubMed ID: 26933813 [TBL] [Abstract][Full Text] [Related]
11. Manufacturing human mesenchymal stem cells at clinical scale: process and regulatory challenges. Jossen V; van den Bos C; Eibl R; Eibl D Appl Microbiol Biotechnol; 2018 May; 102(9):3981-3994. PubMed ID: 29564526 [TBL] [Abstract][Full Text] [Related]
13. International Society for Cell & Gene Therapy Position Paper: Key considerations to support evidence-based cell and gene therapies and oppose marketing of unproven products. Ikonomou L; Cuende N; Forte M; Grilley BJ; Levine AD; Munsie M; Rasko JEJ; Turner L; Bidkhori HR; Ciccocioppo R; Grignon F; Srivastava A; Weiss DJ; Zettler P; Levine BL; Cytotherapy; 2023 Sep; 25(9):920-929. PubMed ID: 37517865 [TBL] [Abstract][Full Text] [Related]
14. The Regulation of Cell Therapy and Gene Therapy Products in Switzerland. Bukovac PK; Hauser M; Lottaz D; Marti A; Schmitt I; Schochat T Adv Exp Med Biol; 2023; 1430():41-58. PubMed ID: 37526841 [TBL] [Abstract][Full Text] [Related]
15. Overview of the Regulatory Oversight Implemented by the French Regulatory Authorities for the Clinical Investigation of Gene Therapy and Cell Therapy Products. Lucas-Samuel S; Ferry N; Trouvin JH Adv Exp Med Biol; 2015; 871():73-85. PubMed ID: 26374213 [TBL] [Abstract][Full Text] [Related]
16. [The Innovation Office of the Paul-Ehrlich-Institut. Regulatory support during the scientific development of ATMP]. Ziegele B; Dahl L; Müller AT Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):857-66. PubMed ID: 21698540 [TBL] [Abstract][Full Text] [Related]
17. The Role of Dissolved Oxygen Levels on Human Mesenchymal Stem Cell Culture Success, Regulatory Compliance, and Therapeutic Potential. Bahsoun S; Coopman K; Forsyth NR; Akam EC Stem Cells Dev; 2018 Oct; 27(19):1303-1321. PubMed ID: 30003826 [TBL] [Abstract][Full Text] [Related]
18. Establishing an Organotypic System for Investigating Multimodal Neural Repair Effects of Human Mesenchymal Stromal Stem Cells. Thakor DK; Wang L; Benedict D; Kabatas S; Zafonte RD; Teng YD Curr Protoc Stem Cell Biol; 2018 Nov; 47(1):e58. PubMed ID: 30021049 [TBL] [Abstract][Full Text] [Related]
19. Scalability and process transfer of mesenchymal stromal cell production from monolayer to microcarrier culture using human platelet lysate. Heathman TR; Stolzing A; Fabian C; Rafiq QA; Coopman K; Nienow AW; Kara B; Hewitt CJ Cytotherapy; 2016 Apr; 18(4):523-35. PubMed ID: 26971681 [TBL] [Abstract][Full Text] [Related]
20. Developing cell therapies as drug products. Ciccocioppo R; Comoli P; Astori G; Del Bufalo F; Prapa M; Dominici M; Locatelli F Br J Pharmacol; 2021 Jan; 178(2):262-279. PubMed ID: 33140850 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]